SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CASI Pharmaceuticals, Inc. – ‘20-F’ for 12/31/23 – ‘EX-101.SCH’

On:  Thursday, 3/28/24, at 11:01am ET   ·   For:  12/31/23   ·   Accession #:  1558370-24-4190   ·   File #:  1-41666

Previous ‘20-F’:  ‘20-F’ on 4/26/23 for 12/31/22   ·   Latest ‘20-F’:  This Filing   ·   15 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  CASI Pharmaceuticals, Inc.        20-F       12/31/23  142:21M                                    Toppan Merrill Bridge/FA

Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual or Annual-Transition Report by a Foreign     HTML   3.52M 
                Non-Canadian Issuer                                              
 2: EX-1.1      Underwriting Agreement or Conflict Minerals Report  HTML   1.36M 
 3: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML     58K 
                Liquidation or Succession                                        
 4: EX-4.29     Instrument Defining the Rights of Security Holders  HTML    230K 
 5: EX-4.37     Instrument Defining the Rights of Security Holders  HTML   1.10M 
 6: EX-4.38     Instrument Defining the Rights of Security Holders  HTML    321K 
 7: EX-4.39     Instrument Defining the Rights of Security Holders  HTML     56K 
 8: EX-4.40     Instrument Defining the Rights of Security Holders  HTML    336K 
 9: EX-4.41     Instrument Defining the Rights of Security Holders  HTML    315K 
10: EX-4.42     Instrument Defining the Rights of Security Holders  HTML    140K 
11: EX-4.43     Instrument Defining the Rights of Security Holders  HTML    128K 
12: EX-4.44     Instrument Defining the Rights of Security Holders  HTML    121K 
13: EX-4.45     Instrument Defining the Rights of Security Holders  HTML    314K 
14: EX-4.46     Instrument Defining the Rights of Security Holders  HTML     92K 
15: EX-4.47     Instrument Defining the Rights of Security Holders  HTML    122K 
16: EX-4.48     Instrument Defining the Rights of Security Holders  HTML     60K 
17: EX-8.1      Opinion of Counsel re: Tax Matters                  HTML     38K 
21: EX-13.1     Annual or Quarterly Report to Security Holders      HTML     41K 
22: EX-13.2     Annual or Quarterly Report to Security Holders      HTML     41K 
24: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     62K 
                Awarded Compensation                                             
18: EX-11.1     Statement re: the Computation of Earnings Per       HTML     67K 
                Share                                                            
19: EX-12.1     Statement re: the Computation of Ratios             HTML     44K 
20: EX-12.2     Statement re: the Computation of Ratios             HTML     44K 
23: EX-15.1     Letter re: Unaudited Interim Financial Info         HTML     38K 
30: R1          Document and Entity Information                     HTML    115K 
31: R2          Consolidated Balance Sheets                         HTML    147K 
32: R3          Consolidated Balance Sheets (Parenthetical)         HTML     50K 
33: R4          Consolidated Statements of Operations and           HTML    185K 
                Comprehensive Loss                                               
34: R5          Consolidated Statements of Stockholders' Equity     HTML     90K 
35: R6          Consolidated Statements of Cash Flows               HTML    188K 
36: R7          Description of Business                             HTML     87K 
37: R8          Summary of Significant Accounting Policies          HTML     96K 
38: R9          Investment in Equity Securities, at Fair Value and  HTML    187K 
                Long-Term Investments                                            
39: R10         Inventories                                         HTML     41K 
40: R11         Leases                                              HTML     89K 
41: R12         Property, Plant and Equipment                       HTML     61K 
42: R13         Intangible Assets                                   HTML    111K 
43: R14         Accrued and Other Current Liabilities, and Other    HTML     76K 
                Liabilities                                                      
44: R15         Short Term Borrowings                               HTML     43K 
45: R16         Notes Payable                                       HTML     45K 
46: R17         Grants                                              HTML     42K 
47: R18         Redeemable Noncontrolling Interest and Long Term    HTML     68K 
                Borrowing                                                        
48: R19         Shareholders' Equity                                HTML     66K 
49: R20         Costs of Revenues                                   HTML     40K 
50: R21         Net Loss Per Share                                  HTML     65K 
51: R22         Employee Benefit Plan                               HTML     42K 
52: R23         Share-Based Compensation                            HTML    182K 
53: R24         Income Taxes                                        HTML    159K 
54: R25         Fair Value Measurements                             HTML    118K 
55: R26         Related Party Transactions                          HTML     48K 
56: R27         Commitments and Contingencies                       HTML     44K 
57: R28         Restricted Net Assets                               HTML     41K 
58: R29         Subsequent Events                                   HTML     41K 
59: R30         Condensed Financial Information of Registrant       HTML    220K 
60: R31         Summary of Significant Accounting Policies          HTML    164K 
                (Policies)                                                       
61: R32         Summary of Significant Accounting Policies          HTML     50K 
                (Tables)                                                         
62: R33         Investment in Equity Securities, at Fair Value and  HTML    170K 
                Long-Term Investments (Tables)                                   
63: R34         Leases (Tables)                                     HTML     88K 
64: R35         Property, Plant and Equipment (Tables)              HTML     57K 
65: R36         Intangible Assets (Tables)                          HTML    111K 
66: R37         Accrued and Other Current Liabilities, and Other    HTML     76K 
                Liabilities (Tables)                                             
67: R38         Redeemable Noncontrolling Interest (Tables)         HTML     61K 
68: R39         Shareholders' Equity (Tables)                       HTML     53K 
69: R40         Net Loss Per Share (Tables)                         HTML     64K 
70: R41         Share-Based Compensation (Tables)                   HTML    180K 
71: R42         Income Taxes (Tables)                               HTML    159K 
72: R43         Fair Value Measurements (Tables)                    HTML    117K 
73: R44         Condensed Financial Information of Registrant       HTML    222K 
                (Tables)                                                         
74: R45         DESCRIPTION OF BUSINESS - Liquidity and Capital     HTML    111K 
                Resources (Details)                                              
75: R46         DESCRIPTION OF BUSINESS - License and Distribution  HTML     51K 
                Agreements (China Resources Pharmaceutical                       
                Commercial Group International Trading Co., Ltd.)                
                (Details)                                                        
76: R47         DESCRIPTION OF BUSINESS - License and Distribution  HTML     50K 
                Agreements (Precision Autoimmune Therapeutics Co.,               
                Ltd) (Details)                                                   
77: R48         DESCRIPTION OF BUSINESS - License and Distribution  HTML     47K 
                Agreements (Juventas Cell Therapy Ltd.) (Details)                
78: R49         DESCRIPTION OF BUSINESS - License and Distribution  HTML     72K 
                Agreements (BioInvent International AB) (Details)                
79: R50         DESCRIPTION OF BUSINESS - License and Distribution  HTML     54K 
                Agreements (Black Belt Therapeutics Limited)                     
                (Details)                                                        
80: R51         DESCRIPTION OF BUSINESS - License and Distribution  HTML     56K 
                Agreements (Cleave Therapeutics, Inc.) (Details)                 
81: R52         DESCRIPTION OF BUSINESS - License and Distribution  HTML     48K 
                Agreements (Pharmathen Global BV) (Details)                      
82: R53         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     41K 
                Consolidation (Details)                                          
83: R54         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     40K 
                Segment Reporting (Details)                                      
84: R55         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash   HTML     47K 
                and Cash Equivalents (Details)                                   
85: R56         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     46K 
                Aggregate Cost And Fair Value (Details)                          
86: R57         Summary of Significant Accounting Policies - Ppe    HTML     48K 
                (Details)                                                        
87: R58         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     66K 
                LONG-TERM INVESTMENTS - Investment in equity                     
                securities, at fair value-MaxCyte Inc. (Details)                 
88: R59         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     94K 
                LONG-TERM INVESTMENTS - Investment in equity                     
                securities, at fair value-BioInvent International                
                AB ordinary shares and warrants (Details)                        
89: R60         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     71K 
                LONG-TERM INVESTMENTS - BioInvent International AB               
                - Summary of Investments (Details)                               
90: R61         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     66K 
                LONG-TERM INVESTMENTS - Summary of Long-term                     
                investments (Details)                                            
91: R62         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     86K 
                LONG-TERM INVESTMENTS - Investment in equity                     
                securities, at fair value-Juventas Cell Therapy                  
                Ltd. (Details)                                                   
92: R63         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     89K 
                LONG-TERM INVESTMENTS - Investment in equity                     
                securities, at fair value-Alesta Therapeutics B.V.               
                (Details)                                                        
93: R64         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     78K 
                LONG-TERM INVESTMENTS - Investment in equity                     
                securities, at fair value-Cleave Therapeutics,                   
                Inc. (Details)                                                   
94: R65         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     75K 
                LONG-TERM INVESTMENTS - Investment in Precision                  
                Autoimmune Therapeutics Co Ltd (Pat) (Details)                   
95: R66         Inventories (Details)                               HTML     43K 
96: R67         Leases - (Details)                                  HTML     57K 
97: R68         Leases - Right of Use Assets and Liabilities        HTML     51K 
                (Details)                                                        
98: R69         LEASES - Supplemental Cash Flow (Details)           HTML     45K 
99: R70         LEASES - Future Undiscounted Cash Flows (Details)   HTML     61K 
100: R71         PROPERTY, PLANT AND EQUIPMENT - Narratives          HTML     50K  
                (Details)                                                        
101: R72         PROPERTY, PLANT AND EQUIPMENT - By type (Details)   HTML     55K  
102: R73         INTANGIBLE ASSETS - Narratives (Details)            HTML     72K  
103: R74         INTANGIBLE ASSETS - Net Definite-lived Intangible   HTML     59K  
                Assets (Details)                                                 
104: R75         INTANGIBLE ASSETS - Intangible Assets Rollforward   HTML     50K  
                (Details)                                                        
105: R76         INTANGIBLE ASSETS - Expected Future Amortization    HTML     52K  
                Expense (Details)                                                
106: R77         Accrued and Other Current Liabilities, and Other    HTML     73K  
                Liabilities (Details)                                            
107: R78         Short Term Borrowings (Details)                     HTML     63K  
108: R79         Notes Payable (Details)                             HTML     50K  
109: R80         Grants (Details)                                    HTML     51K  
110: R81         Redeemable Noncontrolling Interest and Long Term    HTML     96K  
                Borrowing (Details)                                              
111: R82         Redeemable Noncontrolling Interest and Long Term    HTML     51K  
                Borrowing - Changes in Redeemable Noncontrolling                 
                Interest (Details)                                               
112: R83         Shareholders' Equity (Details)                      HTML     83K  
113: R84         Shareholders' Equity - Warrants Activity (Details)  HTML     52K  
114: R85         Costs of Revenues (Details)                         HTML     42K  
115: R86         Net Loss Per Share (Details)                        HTML     43K  
116: R87         Net Loss Per Share - Basic and diluted net loss     HTML     70K  
                per share computation (Details)                                  
117: R88         Employee Benefit Plan (Details)                     HTML     44K  
118: R89         SHARE-BASED COMPENSATION - Compensation Expense     HTML     55K  
                (Details)                                                        
119: R90         SHARE-BASED COMPENSATION - Weighted-Average         HTML     55K  
                Assumptions (Details)                                            
120: R91         SHARE-BASED COMPENSATION - Options Outstanding      HTML     95K  
                (Details)                                                        
121: R92         SHARE-BASED COMPENSATION - Stock Option             HTML     70K  
                Outstanding (Details)                                            
122: R93         Share-Based Compensation (Details)                  HTML     86K  
123: R94         INCOME TAXES - Loss Before Income Taxes (Details)   HTML     50K  
124: R95         INCOME TAXES - Deferred Income Tax Assets And       HTML     72K  
                Liabilities (Details)                                            
125: R96         INCOME TAXES - Reconciliation Of The Provision For  HTML     65K  
                Income Taxes (Details)                                           
126: R97         INCOME TAXES - Valuation allowance (Details)        HTML     47K  
127: R98         INCOME TAXES - Gross Unrecognized Tax Benefits      HTML     45K  
                (Details)                                                        
128: R99         Income Taxes (Details)                              HTML     77K  
129: R100        FAIR VALUE MEASUREMENTS - Financial and             HTML     67K  
                Non-Financial Assets and Liabilities (Details)                   
130: R101        FAIR VALUE MEASUREMENTS - Quantitative Information  HTML     50K  
                about Level 3 Fair Value Measurements (Details)                  
131: R102        Fair Value Measurements (Details)                   HTML     62K  
132: R103        Related Party Transactions (Details)                HTML     83K  
133: R104        Commitments and Contingencies (Details)             HTML     58K  
134: R105        Restricted Net Assets (Details)                     HTML     40K  
135: R106        CONDENSED FINANCIAL INFORMATION OF REGISTRANT -     HTML    150K  
                Condensed Balance Sheets (Details)                               
136: R107        CONDENSED FINANCIAL INFORMATION OF REGISTRANT -     HTML    108K  
                Condensed Statements of Operations and                           
                Comprehensive Loss (Details)                                     
137: R108        CONDENSED FINANCIAL INFORMATION OF REGISTRANT -     HTML    108K  
                Condensed Statements of Cash Flows (Details)                     
139: XML         IDEA XML File -- Filing Summary                      XML    243K  
142: XML         XBRL Instance -- casi-20231231x20f_htm               XML   3.57M  
138: EXCEL       IDEA Workbook of Financial Report Info              XLSX    249K  
26: EX-101.CAL  XBRL Calculations -- casi-20231231_cal               XML    267K 
27: EX-101.DEF  XBRL Definitions -- casi-20231231_def                XML   1.32M 
28: EX-101.LAB  XBRL Labels -- casi-20231231_lab                     XML   1.83M 
29: EX-101.PRE  XBRL Presentations -- casi-20231231_pre              XML   1.74M 
25: EX-101.SCH  XBRL Schema -- casi-20231231                         XSD    324K 
140: JSON        XBRL Instance as JSON Data -- MetaLinks              668±  1.06M  
141: ZIP         XBRL Zipped Folder -- 0001558370-24-004190-xbrl      Zip   1.32M

‘EX-101.SCH’   —   XBRL Schema — casi-20231231

This Exhibit is an XBRL File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 10.5.0.8 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 3/28/2024 2:06:03 PM -->
<!-- Modified on: 3/28/2024 2:06:03 PM -->
<xsd:schema xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" targetNamespace="http://www.entremed.com/20231231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:casi="http://www.entremed.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
<link:definition> 99900 - Disclosure - Standard And Custom Axis Domain Defaults </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition> 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
<link:definition> 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss - Calc 2 </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
<link:definition> 00400 - Statement - Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAggregateCostAndFairValueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAggregateCostAndFairValueDetails">
<link:definition> 40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Aggregate Cost And Fair Value (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" id="DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails">
<link:definition> 40502 - Disclosure - LEASES - Right of Use Assets and Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" id="DisclosureLeasesFutureUndiscountedCashFlowsDetails">
<link:definition> 40504 - Disclosure - LEASES - Future Undiscounted Cash Flows (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetailss" id="DisclosurePropertyPlantAndEquipmentByTypeDetailss">
<link:definition> 40602 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - By type (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetailsCalc2" id="DisclosureLeasesFutureUndiscountedCashFlowsDetailsCalc2">
<link:definition> 40703 - Disclosure - Leases - Future Undiscounted Cash Flows (Details) - Calc 2 </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" id="DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails">
<link:definition> 40801 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails">
<link:definition> 41801 - Disclosure - INCOME TAXES - Loss Before Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails">
<link:definition> 41802 - Disclosure - INCOME TAXES - Deferred Income Tax Assets And Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesReconciliationOfProvisionForIncomeTaxesDetails">
<link:definition> 41803 - Disclosure - INCOME TAXES - Reconciliation Of The Provision For Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" id="DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails">
<link:definition> 42401 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Balance Sheets (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" id="DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails">
<link:definition> 42402 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Operations and Comprehensive Loss (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
<link:definition> 00300 - Statement - Consolidated Statements of Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
<link:definition> 31903 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" id="DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails">
<link:definition> 40101 - Disclosure - DESCRIPTION OF BUSINESS - Liquidity and Capital Resources (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails">
<link:definition> 40102 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails">
<link:definition> 40103 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Precision Autoimmune Therapeutics Co., Ltd) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails">
<link:definition> 40104 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Juventas Cell Therapy Ltd.) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails">
<link:definition> 40105 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (BioInvent International AB) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails">
<link:definition> 40106 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Black Belt Therapeutics Limited) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails">
<link:definition> 40107 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Cleave Therapeutics, Inc.) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" id="DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails">
<link:definition> 40108 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Pharmathen Global BV) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConsolidationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConsolidationDetails">
<link:definition> 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
<link:definition> 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails">
<link:definition> 40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueMaxcyteIncDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueMaxcyteIncDetails">
<link:definition> 40301 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-MaxCyte Inc. (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails">
<link:definition> 40302 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-BioInvent International AB ordinary shares and warrants (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails">
<link:definition> 40303 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - BioInvent International AB - Summary of Investments (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails">
<link:definition> 40304 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Summary of Long-term investments (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueJuventasCellTherapyLtdDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueJuventasCellTherapyLtdDetails">
<link:definition> 40305 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Juventas Cell Therapy Ltd. (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails">
<link:definition> 40306 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Alesta Therapeutics B.V. (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails">
<link:definition> 40307 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Cleave Therapeutics, Inc. (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails">
<link:definition> 40308 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in Precision Autoimmune Therapeutics Co Ltd (PAT) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
<link:definition> 40401 - Disclosure - INVENTORIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
<link:definition> 40501 - Disclosure - LEASES - (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentNarrativesDetails" id="DisclosurePropertyPlantAndEquipmentNarrativesDetails">
<link:definition> 40601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narratives (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails" id="DisclosureIntangibleAssetsNarrativesDetails">
<link:definition> 40701 - Disclosure - INTANGIBLE ASSETS - Narratives (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" id="DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails">
<link:definition> 40702 - Disclosure - INTANGIBLE ASSETS - Net Definite-lived Intangible Assets (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" id="DisclosureShortTermBorrowingsDetails">
<link:definition> 40901 - Disclosure - SHORT TERM BORROWINGS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNotesPayableDetails" id="DisclosureNotesPayableDetails">
<link:definition> 41001 - Disclosure - NOTES PAYABLE (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureGrantsDetails" id="DisclosureGrantsDetails">
<link:definition> 41101 - Disclosure - GRANTS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" id="DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails">
<link:definition> 41201 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND LONG TERM BORROWING (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareholdersEquityDetails" id="DisclosureShareholdersEquityDetails">
<link:definition> 41301 - Disclosure - SHAREHOLDERS' EQUITY (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCostsOfRevenuesDetails" id="DisclosureCostsOfRevenuesDetails">
<link:definition> 41401 - Disclosure - COSTS OF REVENUES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
<link:definition> 41501 - Disclosure - NET LOSS PER SHARE (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" id="DisclosureShareBasedCompensationCompensationExpenseDetails">
<link:definition> 41701 - Disclosure - SHARE-BASED COMPENSATION - Compensation Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" id="DisclosureShareBasedCompensationOptionsOutstandingDetails">
<link:definition> 41703 - Disclosure - SHARE-BASED COMPENSATION - Options Outstanding (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" id="DisclosureShareBasedCompensationStockOptionOutstandingDetails">
<link:definition> 41704 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Outstanding (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
<link:definition> 41705 - Disclosure - SHARE-BASED COMPENSATION (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
<link:definition> 41806 - Disclosure - INCOME TAXES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" id="DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails">
<link:definition> 41901 - Disclosure - FAIR VALUE MEASUREMENTS - Financial and Non-Financial Assets and Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails">
<link:definition> 41902 - Disclosure - FAIR VALUE MEASUREMENTS - Quantitative Information about Level 3 Fair Value Measurements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
<link:definition> 41903 - Disclosure - FAIR VALUE MEASUREMENTS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
<link:definition> 42001 - Disclosure - RELATED PARTY TRANSACTIONS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
<link:definition> 42101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" id="DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails">
<link:definition> 42403 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Cash Flows (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
<link:definition> 10101 - Disclosure - DESCRIPTION OF BUSINESS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
<link:definition> 10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestments" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestments">
<link:definition> 10301 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInventories" id="DisclosureInventories">
<link:definition> 10401 - Disclosure - INVENTORIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeases" id="DisclosureLeases">
<link:definition> 10501 - Disclosure - LEASES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosurePropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipment">
<link:definition> 10601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
<link:definition> 10701 - Disclosure - INTANGIBLE ASSETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilities" id="DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilities">
<link:definition> 10801 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShortTermBorrowings" id="DisclosureShortTermBorrowings">
<link:definition> 10901 - Disclosure - SHORT TERM BORROWINGS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
<link:definition> 11001 - Disclosure - NOTES PAYABLE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureGrants" id="DisclosureGrants">
<link:definition> 11101 - Disclosure - GRANTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowing" id="DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowing">
<link:definition> 11201 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND LONG TERM BORROWING </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
<link:definition> 11301 - Disclosure - SHAREHOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCostsOfRevenues" id="DisclosureCostsOfRevenues">
<link:definition> 11401 - Disclosure - COSTS OF REVENUES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
<link:definition> 11501 - Disclosure - NET LOSS PER SHARE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
<link:definition> 11601 - Disclosure - EMPLOYEE BENEFIT PLAN </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
<link:definition> 11701 - Disclosure - SHARE-BASED COMPENSATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11801 - Disclosure - INCOME TAXES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
<link:definition> 11901 - Disclosure - FAIR VALUE MEASUREMENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
<link:definition> 12001 - Disclosure - RELATED PARTY TRANSACTIONS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
<link:definition> 12101 - Disclosure - COMMITMENTS AND CONTINGENCIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRestrictedNetAssets" id="DisclosureRestrictedNetAssets">
<link:definition> 12201 - Disclosure - RESTRICTED NET ASSETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
<link:definition> 12301 - Disclosure - SUBSEQUENT EVENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrant" id="DisclosureCondensedFinancialInformationOfRegistrant">
<link:definition> 12401 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition> 20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
<link:definition> 30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsTables" id="DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsTables">
<link:definition> 30303 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
<link:definition> 30503 - Disclosure - LEASES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentTables" id="DisclosurePropertyPlantAndEquipmentTables">
<link:definition> 30603 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
<link:definition> 30703 - Disclosure - INTANGIBLE ASSETS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTables" id="DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTables">
<link:definition> 30803 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestTables" id="DisclosureRedeemableNoncontrollingInterestTables">
<link:definition> 31203 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareholdersEquityTables" id="DisclosureShareholdersEquityTables">
<link:definition> 31303 - Disclosure - SHAREHOLDERS' EQUITY (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
<link:definition> 31503 - Disclosure - NET LOSS PER SHARE (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
<link:definition> 31703 - Disclosure - SHARE-BASED COMPENSATION (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
<link:definition> 31803 - Disclosure - INCOME TAXES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantTables" id="DisclosureCondensedFinancialInformationOfRegistrantTables">
<link:definition> 32401 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingDetails">
<link:definition> 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails" id="DisclosureLeasesSupplementalCashFlowDetails">
<link:definition> 40503 - Disclosure - LEASES - Supplemental Cash Flow (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" id="DisclosurePropertyPlantAndEquipmentByTypeDetails">
<link:definition> 40602 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - By type (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails" id="DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails">
<link:definition> 40703 - Disclosure - INTANGIBLE ASSETS - Intangible Assets Rollforward (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" id="DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails">
<link:definition> 40704 - Disclosure - INTANGIBLE ASSETS - Expected Future Amortization Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails" id="DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails">
<link:definition> 41202 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND LONG TERM BORROWING - Changes in Redeemable Noncontrolling Interest (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareholdersEquityWarrantsActivityDetails" id="DisclosureShareholdersEquityWarrantsActivityDetails">
<link:definition> 41302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails">
<link:definition> 41502 - Disclosure - NET LOSS PER SHARE - Basic and diluted net loss per share computation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
<link:definition> 41601 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" id="DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails">
<link:definition> 41702 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Assumptions (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" id="DisclosureIncomeTaxesValuationAllowanceDetails">
<link:definition> 41804 - Disclosure - INCOME TAXES - Valuation allowance (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
<link:definition> 41805 - Disclosure - INCOME TAXES - Gross Unrecognized Tax Benefits (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.entremed.com/role/DisclosureRestrictedNetAssetsDetails" id="DisclosureRestrictedNetAssetsDetails">
<link:definition> 42201 - Disclosure - RESTRICTED NET ASSETS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="casi-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="casi-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="casi-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="casi-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd"/>
<xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
<xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:element id="casi_AccretionOfRedeemableNonControllingInterest" name="AccretionOfRedeemableNonControllingInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element name="ResearchAndDevelopmentInProcessAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="casi_ResearchAndDevelopmentInProcessAcquired" substitutionGroup="xbrli:item" xbrli:balance="debit"/>
<xsd:element id="casi_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock" name="DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_CasiChinaMember" name="CasiChinaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_CASIWuxiMember" name="CASIWuxiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_DescriptionOfBusinessAndBasisOfPresentationLineItems" name="DescriptionOfBusinessAndBasisOfPresentationLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="casi_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" substitutionGroup="xbrli:item"/>
<xsd:element id="casi_AbbreviatedNewDrugApplicationsMember" name="AbbreviatedNewDrugApplicationsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_InvestmentCommitment" name="InvestmentCommitment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="casi_InitialCashInvestment" name="InitialCashInvestment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="SelectedAndasToBeTransferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="casi_SelectedAndasToBeTransferred" substitutionGroup="xbrli:item" xbrli:balance="credit"/>
<xsd:element id="casi_LongTermIncentivePlan2011Member" name="LongTermIncentivePlan2011Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms" substitutionGroup="xbrli:item"/>
<xsd:element name="ShareBasedPaymentCashReceivedFromStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="casi_ShareBasedPaymentCashReceivedFromStockOptionExercises" substitutionGroup="xbrli:item" xbrli:balance="debit"/>
<xsd:element name="PerformanceShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="casi_PerformanceShareBasedCompensationExpense" substitutionGroup="xbrli:item" xbrli:balance="debit"/>
<xsd:element id="casi_EVOMELAMember" name="EVOMELAMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_CallOptionToPurchaseInvestmentPeriod" name="CallOptionToPurchaseInvestmentPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_BlackBeltTxLimitedMember" name="BlackBeltTxLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_JuventasCellTherapyLtdMember" name="JuventasCellTherapyLtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_UpfrontPayment" name="UpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_NumberOfOperatingLeases" name="NumberOfOperatingLeases" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_BlackBeltTherapeuticsLimitedMember" name="BlackBeltTherapeuticsLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_ScheduleOfDescriptionOfBusinessAndBasisOfPresentationTable" name="ScheduleOfDescriptionOfBusinessAndBasisOfPresentationTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_FurnitureAndEquipmentGross" name="FurnitureAndEquipmentGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_ScheduleOfNotesPayableTable" name="ScheduleOfNotesPayableTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_NotesPayableLineItems" name="NotesPayableLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_RangeOneMember" name="RangeOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_RangeTwoMember" name="RangeTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_RangeThreeMember" name="RangeThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_RangeFourMember" name="RangeFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod" name="UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_EmergingTechnologyPartnersLLCMember" name="EmergingTechnologyPartnersLLCMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_SecuritiesPurchaseAgreementsAbstract" name="SecuritiesPurchaseAgreementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_HcWainwrightCoLlcMember" name="HcWainwrightCoLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_PerformanceBasedOptionMember" name="PerformanceBasedOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_PharmathenGlobalBvMember" name="PharmathenGlobalBvMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_NonRoyaltyExclusiveDistributionPeriod" name="NonRoyaltyExclusiveDistributionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueThereafter" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="casi_InvestmentsContractCounterpartyAxis" name="InvestmentsContractCounterpartyAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_InvestmentsContractCounterpartyDomain" name="InvestmentsContractCounterpartyDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_AdditionalMilestonePayments" name="AdditionalMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="casi_PrepaidOperatingLeasePayments" name="PrepaidOperatingLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="casi_RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment" name="RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_IncomeTaxReconciliationAttributeExpirationAmount" name="IncomeTaxReconciliationAttributeExpirationAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_NonFinancialAssetsFairValueDisclosure" name="NonFinancialAssetsFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="casi_ReductionInCarryingAmountOfRightOfUseAssets" name="ReductionInCarryingAmountOfRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_ProceedsFromGovernmentGrant" name="ProceedsFromGovernmentGrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_MTBankMember" name="MTBankMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_LoansAdvancedToRelatedPartyTerm" name="LoansAdvancedToRelatedPartyTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_LoansAdvancedToRelatedPartyConversionMinimumEquityFinancingRoundAmount" name="LoansAdvancedToRelatedPartyConversionMinimumEquityFinancingRoundAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="casi_LoansAdvancedToRelatedPartyConversionPercentageOfPerSharePrice" name="LoansAdvancedToRelatedPartyConversionPercentageOfPerSharePrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="casi_GrantsDisclosureAbstract" name="GrantsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_GrantsDisclosureTextBlock" name="GrantsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_GrantsDisclosureTable" name="GrantsDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_GrantsDisclosureLineItems" name="GrantsDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements" name="StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="casi_StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements" name="StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_ReceiptOfGovernmentGrant" name="ReceiptOfGovernmentGrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_GrantsEligible" name="GrantsEligible" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_AmortizationOfIntangibleAssetsAndHeldForSale" name="AmortizationOfIntangibleAssetsAndHeldForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_EquityMethodInvestmentInvestmentToBeMade" name="EquityMethodInvestmentInvestmentToBeMade" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="casi_NumberOfSharesToBeSubscribed" name="NumberOfSharesToBeSubscribed" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_NumberOfNewWarrantsSubscribed" name="NumberOfNewWarrantsSubscribed" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_SubscriptionPeriodForWarrants" name="SubscriptionPeriodForWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_LoansAdvancedToRelatedPartyAmountOfEqualInstallments" name="LoansAdvancedToRelatedPartyAmountOfEqualInstallments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted" name="LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_BioinventInternationalAbMember" name="BioinventInternationalAbMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_ScheduleOfLongTermInvestmentsTableTextBlock" name="ScheduleOfLongTermInvestmentsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_ScheduleOfLongTermInvestmentsTable" name="ScheduleOfLongTermInvestmentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_ScheduleOfLongTermInvestmentsLineItems" name="ScheduleOfLongTermInvestmentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput" name="EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_LicenseAgreementMilestonePayment" name="LicenseAgreementMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_LoanToBeAdvanced" name="LoanToBeAdvanced" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_PublicOfferingPrice" name="PublicOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_WarrantsAndRightsOutstandingFairValueDisclosure" name="WarrantsAndRightsOutstandingFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_ChinaCiticBankCorporationLimitedMember" name="ChinaCiticBankCorporationLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_AdditionalEquityMethodInvestmentsPurchased" name="AdditionalEquityMethodInvestmentsPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod" name="UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_ChairmanAndChiefExecutiveOfficerMember" name="ChairmanAndChiefExecutiveOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_MaxcyteIncMember" name="MaxcyteIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_NumberOfWarrantsSubscribedPerShare" name="NumberOfWarrantsSubscribedPerShare" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="casi_RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments" name="RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="casi_InvestmentsInEquityWarrantsMember" name="InvestmentsInEquityWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_NumberMilestonesAchieved" name="NumberMilestonesAchieved" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_NumberMilestonesPaymentsOutstanding" name="NumberMilestonesPaymentsOutstanding" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="casi_FurnitureAndEquipmentMember" name="FurnitureAndEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_CleaveTherapeuticsIncMember" name="CleaveTherapeuticsIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_InvestmentInConvertibleNote" name="InvestmentInConvertibleNote" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_InvestmentsFairValueDisclosureConvertibleLoan" name="InvestmentsFairValueDisclosureConvertibleLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_OppenheimerAndCo.IncMember" name="OppenheimerAndCo.IncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_PotentialMilestonePaymentAndRoyalty" name="PotentialMilestonePaymentAndRoyalty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_FairValueCarryingAmount" name="FairValueCarryingAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_InvestmentsFairValueDisclosureConvertibleLoanMeasuredAtFairValueThroughProfitAndLoss" name="InvestmentsFairValueDisclosureConvertibleLoanMeasuredAtFairValueThroughProfitAndLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_InvestmentsFairValueDisclosureWarrantsMeasuredAtFairValueThroughProfitAndLoss" name="InvestmentsFairValueDisclosureWarrantsMeasuredAtFairValueThroughProfitAndLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_LongTermIncentivePlan2021Member" name="LongTermIncentivePlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_AlestaTxMember" name="AlestaTxMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="casi_ProceedsFromEquityFinancing" name="ProceedsFromEquityFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="casi_EquityMethodInvestmentsContribution" name="EquityMethodInvestmentsContribution" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="casi_EquityMethodInvestmentsExchangeOfCommonStocks" name="EquityMethodInvestmentsExchangeOfCommonStocks" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="DebtInstrumentDecreaseInterestForgiveness" id="casi_DebtInstrumentDecreaseInterestForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ReceiptOfRepaymentOfConvertibleNote" id="casi_ReceiptOfRepaymentOfConvertibleNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="NotesPayableForgiven" id="casi_NotesPayableForgiven" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="CostsOfRevenuesAbstract" id="casi_CostsOfRevenuesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="CostsOfRevenuesTextBlock" id="casi_CostsOfRevenuesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="PercentageRoyaltiesRequiredToBePaidPeriod" id="casi_PercentageRoyaltiesRequiredToBePaidPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ConstructionAgreementsAxis" id="casi_ConstructionAgreementsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ConstructionAgreementsDomain" id="casi_ConstructionAgreementsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="FullyDilutedCapitalPercentage" id="casi_FullyDilutedCapitalPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="GovernmentGrant" id="casi_GovernmentGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="StockSaleAgreementMember" id="casi_StockSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock" id="casi_AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock" id="casi_ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="TimeBasedStockOptionsMember" id="casi_TimeBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="DeferredTaxLiabilitiesRoyaltyIncome" id="casi_DeferredTaxLiabilitiesRoyaltyIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="NonCashInvestingLoanForgiveness" id="casi_NonCashInvestingLoanForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="TaxCreditCarryforwardExpirationPeriod" id="casi_TaxCreditCarryforwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="PayablesRelatedToPropertyAndEquipmentCurrent" id="casi_PayablesRelatedToPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="NonRoyaltyExclusiveDistributionAdditionalPeriod" id="casi_NonRoyaltyExclusiveDistributionAdditionalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="AvailableForSaleDebtSecuritiesMember" id="casi_AvailableForSaleDebtSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="SecuritiesMeasuredAtFairValueMember" id="casi_SecuritiesMeasuredAtFairValueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="EquitySecuritiesWithoutReadilyDeterminableFairValueMember" id="casi_EquitySecuritiesWithoutReadilyDeterminableFairValueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="UnrealizedLoss" id="casi_UnrealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments" id="casi_DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="EastWestBankMember" id="casi_EastWestBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="NumberOfInstallmentsForUpfrontPayment" id="casi_NumberOfInstallmentsForUpfrontPayment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PercentageOfEquityHeldInJointVenture" id="casi_PercentageOfEquityHeldInJointVenture" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="AggregateConsiderationForEquityInvestment" id="casi_AggregateConsiderationForEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="PrecisionAutoimmuneTherapeuticsCo.LtdMember" id="casi_PrecisionAutoimmuneTherapeuticsCo.LtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="TermDepositNoncurrent" id="casi_TermDepositNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax" id="casi_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="PercentageOfInterestInBoardSeats" id="casi_PercentageOfInterestInBoardSeats" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="EquityMethodInvestmentShares" id="casi_EquityMethodInvestmentShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="LicenseAgreementDevelopmentMilestonePaymentPayable" id="casi_LicenseAgreementDevelopmentMilestonePaymentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LicenseAgreementSalesMilestonePaymentPayable" id="casi_LicenseAgreementSalesMilestonePaymentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LicenseAgreementRefundFromTerminationOfAgreement" id="casi_LicenseAgreementRefundFromTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="InvestmentInSubsidiaries" id="casi_InvestmentInSubsidiaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="IntercompanyOperatingExpenses" id="casi_IntercompanyOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="RestrictedNetAssetsAbstract" id="casi_RestrictedNetAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="RestrictedNetAssetsTextBlock" id="casi_RestrictedNetAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="GrantsRelatedToLandUseRightCurrent" id="casi_GrantsRelatedToLandUseRightCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="SalesAndMarketingServicesPayableCurrent" id="casi_SalesAndMarketingServicesPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ClinicalStudyServicePayableCurrent" id="casi_ClinicalStudyServicePayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ProfessionalConsultingServicePayableCurrent" id="casi_ProfessionalConsultingServicePayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="IntercompanyPayablesCurrent" id="casi_IntercompanyPayablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="OwnershipPercentage" id="casi_OwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization" id="casi_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="TotalUnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod" id="casi_TotalUnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriodRelatedToNonProbableConditionOptions" id="casi_UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriodRelatedToNonProbableConditionOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="OperatingLeaseRightOfUseReturned" id="casi_OperatingLeaseRightOfUseReturned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCo.Ltd.Member" id="casi_ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCo.Ltd.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="SublicensingRevenueFromRelatedParty" id="casi_SublicensingRevenueFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ResearchAndDevelopmentInProcess1" id="casi_ResearchAndDevelopmentInProcess1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ProceedsFromReimbursementOfLaborPreclinicalAndClinalExpense" id="casi_ProceedsFromReimbursementOfLaborPreclinicalAndClinalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="NumberOfAbbreviatedNewDrugApplications" id="casi_NumberOfAbbreviatedNewDrugApplications" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="MachineryAndLabEquipmentMember" id="casi_MachineryAndLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="FolotynMember" id="casi_FolotynMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="FiniteLivedIntangibleAssetsAccumulatedImpairment" id="casi_FiniteLivedIntangibleAssetsAccumulatedImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="PercentageOfValuationAllowanceRecognized" id="casi_PercentageOfValuationAllowanceRecognized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="NumberOfGuaranteeAgreements" id="casi_NumberOfGuaranteeAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="InvestmentPrincipalReturned" id="casi_InvestmentPrincipalReturned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="InvestmentPrincipal" id="casi_InvestmentPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="WuxiLpMember" id="casi_WuxiLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InvestmentReturnPayableInInstallments" id="casi_InvestmentReturnPayableInInstallments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ConvertibleLoanMember" id="casi_ConvertibleLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="TermOfAnniversaryAfterMaturityOfLoan" id="casi_TermOfAnniversaryAfterMaturityOfLoan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ReductionInRegisteredCapital" id="casi_ReductionInRegisteredCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="LicenseAgreementAmountPayable" id="casi_LicenseAgreementAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LicenseAgreementWithMundipharmaInternationalCorporationLimitedMember" id="casi_LicenseAgreementWithMundipharmaInternationalCorporationLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="LicenseAgreementOneTimePaymentPayableUponCompletionOfQualityAudit" id="casi_LicenseAgreementOneTimePaymentPayableUponCompletionOfQualityAudit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="PercentageOfNetSales" id="casi_PercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="LicenseAgreementAggregateAmountPayableInQuarterlyInstallment" id="casi_LicenseAgreementAggregateAmountPayableInQuarterlyInstallment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="TermOfAgreement" id="casi_TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ExclusiveDistributionAgreementMember" id="casi_ExclusiveDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="AssignmentAgreementWithCleaveMember" id="casi_AssignmentAgreementWithCleaveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="AssignmentAgreementCommercialAndSalesMilestonePaymentsPayable" id="casi_AssignmentAgreementCommercialAndSalesMilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="AssignmentAgreementPercentageOfRoyaltyOnNetSalesPayable" id="casi_AssignmentAgreementPercentageOfRoyaltyOnNetSalesPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PurchaseOfShortTermInvestmentsAndTermDeposits" id="casi_PurchaseOfShortTermInvestmentsAndTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ProceedsFromSalesOrMaturityOfShortTermInvestmentsAndTermDeposits" id="casi_ProceedsFromSalesOrMaturityOfShortTermInvestmentsAndTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ProceedsFromExtinguishmentOfInvestmentInConvertibleLoan" id="casi_ProceedsFromExtinguishmentOfInvestmentInConvertibleLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="AmountPayableForAdvancedProcurementOfNewActivePharmaceuticalIngredientsUponAchievementOfConditions" id="casi_AmountPayableForAdvancedProcurementOfNewActivePharmaceuticalIngredientsUponAchievementOfConditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="AcrotechBiopharmaL.l.c.Member" id="casi_AcrotechBiopharmaL.l.c.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="EstimatedShareBasedCompensationExpense" id="casi_EstimatedShareBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ShareBasedCompensationExpenseToBePaidOverRemainingVestingPeriod" id="casi_ShareBasedCompensationExpenseToBePaidOverRemainingVestingPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ShortTermInvestmentsPolicyTextBlock" id="casi_ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ProfitSharingLiabilityNonCurrent" id="casi_ProfitSharingLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="RightOfUseAssetsRemeasured" id="casi_RightOfUseAssetsRemeasured" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ImpairmentLossOfLongTermInvestments" id="casi_ImpairmentLossOfLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment" id="casi_DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="InvestmentEquitySecuritiesFairValue" id="casi_InvestmentEquitySecuritiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="DeemedDividendsAdjustment" id="casi_DeemedDividendsAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="InterestAndDividendsPayableNonCurrent" id="casi_InterestAndDividendsPayableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LicenseAgreementUpfrontPayment" id="casi_LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="RedeemableNonControllingInterestAndLongTermBorrowingAbstract" id="casi_RedeemableNonControllingInterestAndLongTermBorrowingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="RedeemableNonControllingInterestAndLongTermBorrowingTextBlock" id="casi_RedeemableNonControllingInterestAndLongTermBorrowingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="InstallmentOneMember" id="casi_InstallmentOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InstallmentTwoMember" id="casi_InstallmentTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InstallmentThreeMember" id="casi_InstallmentThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InstallmentFourMember" id="casi_InstallmentFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ShortTermInvestmentsFairValue" id="casi_ShortTermInvestmentsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="LicenseAgreementAmountPayableOnCompletionOfAuditAndDeferredQuarterlyPaymentsBecomesDueImmediatelyUponEventOfNonPayment" id="casi_LicenseAgreementAmountPayableOnCompletionOfAuditAndDeferredQuarterlyPaymentsBecomesDueImmediatelyUponEventOfNonPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="CollaborativeArrangementAdditionalAmountPayable" id="casi_CollaborativeArrangementAdditionalAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="SupplyAgreementWithAcrotechInc.Member" id="casi_SupplyAgreementWithAcrotechInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="CollaborativeArrangementAdditionalAmountPayableNumberOfInstallments" id="casi_CollaborativeArrangementAdditionalAmountPayableNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="LongTermDepositsFairValueDisclosure" id="casi_LongTermDepositsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="IncreaseDecreaseInDeferredTaxAssets" id="casi_IncreaseDecreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="DeferredTaxAssetsForeignCurrencyTranslationAdjustment" id="casi_DeferredTaxAssetsForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="DeferredTaxAssetsLeaseLiabilities" id="casi_DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="DeferredTaxLiabilitiesRightOfUseAssets" id="casi_DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="UnderpaymentOfTaxesStatueOfLimitationExtendedTerm" id="casi_UnderpaymentOfTaxesStatueOfLimitationExtendedTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareOptionsTaxShortfallsAmount" id="casi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareOptionsTaxShortfallsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="IntercompanyReceivables" id="casi_IntercompanyReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
</xsd:schema>

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/03/24  CASI Pharmaceuticals, Inc.        F-3                    4:521K

14 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/23/23  CASI Pharmaceuticals, Inc.        S-8 POS     5/23/23    3:156K                                   Toppan Merrill/FA
 4/26/23  CASI Pharmaceuticals, Inc.        20-F       12/31/22  129:16M                                    Toppan Merrill Bridge/FA
 1/31/23  CASI Pharmaceuticals, Inc.        F-4                   22:2.7M                                   Toppan Merrill/FA
11/14/22  CASI Pharmaceuticals, Inc. (DE)   10-Q        9/30/22   74:7.2M                                   Toppan Merrill Bridge/FA
 8/12/22  CASI Pharmaceuticals, Inc. (DE)   10-Q        6/30/22   76:8.1M                                   Toppan Merrill Bridge/FA
12/10/21  CASI Pharmaceuticals, Inc. (DE)   8-K:5,9    12/08/21   12:219K                                   Toppan Merrill/FA
 3/30/21  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/20  109:13M                                    Toppan Merrill Bridge/FA
11/09/20  CASI Pharmaceuticals, Inc. (DE)   10-Q        9/30/20   91:7.2M                                   Toppan Merrill/FA
 3/16/20  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/19   98:6.9M                                   Toppan Merrill/FA
 8/09/19  CASI Pharmaceuticals, Inc. (DE)   10-Q        6/30/19   75:16M                                    Toppan Merrill/FA
 5/15/19  CASI Pharmaceuticals, Inc. (DE)   10-Q        3/31/19   78:5.6M                                   Toppan Merrill/FA
 3/29/19  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/18   91:7.7M                                   Toppan Merrill/FA
 8/14/17  CASI Pharmaceuticals, Inc. (DE)   10-Q        6/30/17   40:1.7M                                   Toppan Merrill/FA
 4/17/07  CASI Pharmaceuticals, Inc.        8-K:5,8,9   4/16/07    9:152K                                   Bowne - DC/FA
↑Top
Filing Submission 0001558370-24-004190   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 16, 9:08:54.1pm ET